ArticleIn vivo (Athens, Greece)
5-Azacytidine Enhances Differentiation of Human Placenta-derived Mesenchymal Stem Cells Towards Schwann-like Cells.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimMesenchymal stem cells (MSCs) can be used for regenerative medicine, particularly in the treatment of neurodegenerative diseases and peripheral nerve injuries. Among these, human placenta-derived mesenchymal stem cells (hPMSCs) possess a high potential for differentiation into various cell types, including those of the neural lineage under appropriate conditions. The primary aim of this study was to isolate and induce the differentiation of hPMSCs into Schwann cell-like cells (SC-like cells) that function to support and play a role in the peripheral nervous system. MATERIALS AND
methodsHuman placental tissues were isolated, and hPMSCs were cultured and characterized. The isolated hPMSCs were positive for mesenchymal stem cell surface markers CD73, CD90, and CD105. The multipotency of hPMSCs was confirmed by their ability to differentiate into osteocytes, chondrocytes, and adipocytes. To induce Schwann cell differentiation, hPMSCs were cultured in Schwann cell differentiation medium with or without the addition of 5-azacytidine (5-aza). Gene and protein expression analyses were performed to assess Schwann cell-specific markers.
resultsAfter 14 days of induction, hPMSCs differentiated in Schwann cell differentiation medium showed significant upregulation of Schwann cell-specific genes S100β, P75, GFAP, and PMP22 (
conclusionThis study demonstrates that hPMSCs can be successfully differentiated into Schwann cell-like cells. The addition of 5-aza significantly promoted this differentiation, leading to higher expression of Schwann cell-specific genes and proteins. These findings suggest that 5-aza plays a supportive role in enhancing Schwann cell differentiation from hPMSCs and may provide a promising approach for future clinical applications in peripheral nerve regeneration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.